Growing Pains from The Islet Cell Transplant World

Type one diabetes (T1D) is a disease with profound implications for patients' quality of life, morbidity and mortality. The incidence of T1D is increasing and its treatment, although improving, continues to be challenging. Tight glycemic control can decrease the incidence and progression of diabetic complications (1). However, this therapeutic goal is not easy to achieve, often interferes with quality of life and can be associated with severe hypoglycemia. Consequently, the need to develop better treatment strategies for T1D, including clinical islet cell transplantation (CICT), remains imperative.